Literature DB >> 9498780

Type 1- and type 2-like lesional skin-derived Mycobacterium leprae-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively.

C E Verhagen1, T C van der Pouw Kraan, A A Buffing, M A Chand, W R Faber, L A Aarden, P K Das.   

Abstract

In an earlier study, we generated a large number of Mycobacterium leprae-responsive and M. leprae-nonresponsive T cell clones (TCC) from the lesional skin of immunologic unstable borderline leprosy patients. In that study, we divided TCC into type 1- and type 2-like on the basis of their IFN-gamma and IL-4 expression. To explore whether other cytokines are coproduced along with IFN-gamma and IL-4, we investigated the secretion of a panel of other cytokines (TNF-alpha, IL-5, IL-6, IL-10, and IL-13) by a large number of these TCC. Upon analysis of 139 M. leprae-responsive TCC, we observed a positive correlation in the coproduction of IFN-gamma/TNF-alpha (r = 0.81), and in that of IL-4/IL-5 (r = 0.83), IL-4/IL-13 (r = 0.80), and IL-5/IL-13 (r = 0.82). Polarized type 1-like TCC produced dominantly IFN-gamma/TNF-alpha, and polarized type 2-like TCC predominantly IL-4/IL-5/IL-13. Most type 0-like TCC produced both sets of cytokines. In contrast, type 1- and type 2-like subsets of M. leprae-nonresponsive TCC (n = 58) did not show the same coexpression of these cytokines. Furthermore, when the differential expression of a broad panel of cytokines by individual M. leprae-responsive TCC is considered, it appeared that additional phenotypes could be recognized. These results suggested that distinct isotypes of type 1- and type 2-like T cells, based on the secretion of a panel of cytokines, may reflect M. leprae-specific characteristics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498780

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  The Rubino test for leprosy is a beta2-glycoprotein 1-dependent antiphospholipid reaction.

Authors:  A Panunto-Castelo; I C Almeida; J C Rosa; L J Greene; M Roque-Barreira
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

2.  Presence of intestinal helminths decreases T helper type 1 responses in tuberculoid leprosy patients and may increase the risk for multi-bacillary leprosy.

Authors:  L M Diniz; E F L Magalhães; F E L Pereira; R Dietze; R Ribeiro-Rodrigues
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

3.  T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection.

Authors:  B M Saunders; H Briscoe; W J Britton
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

4.  NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13.

Authors:  S de la Barrera; M Finiasz; S Fink; J Ilarregui; M Aleman; L Olivares; M C Franco; G Pizzariello; M del Carmen Sasiain
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Synergism of gamma interferon and interleukin-5 in the control of murine filariasis.

Authors:  Michael Saeftel; Manuela Arndt; Sabine Specht; Lars Volkmann; Achim Hoerauf
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

6.  Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes.

Authors:  Harry D Dawson; Gary Collins; Robert Pyle; Michael Key; Ashani Weeraratna; Vishwa Deep-Dixit; Celeste N Nadal; Dennis D Taub
Journal:  BMC Immunol       Date:  2006-11-21       Impact factor: 3.615

7.  T helper cell polarisation as a measure of the maturation of the immune response.

Authors:  Scott B Cameron; Ellen H Stolte; Anthony W Chow; Huub F J Savelkoul
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

8.  Anti-Lipoarabinomannan-Specific Salivary IgA as Prognostic Marker for Leprosy Reactions in Patients and Cellular Immunity in Contacts.

Authors:  André Alan Nahas; Mayara Ingrid de Sousa Lima; Isabela Maria Bernardes Goulart; Luiz Ricardo Goulart
Journal:  Front Immunol       Date:  2018-05-30       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.